Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pramipexole fixed doses in RLS
NCT00390689Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2006
- Primary completion
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pramipexole in restless legs syndrome (RLS) (3 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change From Baseline in International Restless Legs Syndrome (IRLS) Total Score at 6 weeks. Started Oct 2006; status: completed.
02
Drugs
pramipexole
03
Conditions
restless legs syndrome (RLS)
Beyond the preview
Go deeper on NCT00390689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00390689.